Oliver Gautschi

University of Bern — Switzerland

Medicine · Health Sciences

60h-index17.0kcitations478works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(238), Lung Cancer Research Studies(81), Lung Cancer Diagnosis and Treatment(77), Cancer Genomics and Diagnostics(60), Spine and Intervertebral Disc Pathology(49)

Publications476 total

Supplementary Table S2 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2025Open Access
Supplementary Figure S2 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2025Open Access
Supplementary Figure S5 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2025Open Access
Supplementary Table S1 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2025Open Access
Supplementary Figure S3 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2025Open Access
Supplementary Figure S4 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2025Open Access
Supplementary Figure S1 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2025Open Access
Supplementary Figure S6 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2025Open Access
P3.12.06 Pralsetinib (Phase 1/2 ARROW Trial) Compared With Best Available Therapy (External Control) in Pretreated RET Fusion+ NSCLC
Journal of Thoracic Oncology·2025
EP.06.83 Prognostic Impact of PD-L1 Expression in a Swiss Cohort ofEGFR-Mutant Non-Small Cell Lung Cancer Patients Treated With First-Line Osimertinib
Journal of Thoracic Oncology·2025
Effectiveness of a Nurse-Led Patient Education for Oncology Patients to Promote Self-Management in Pain Therapy – An Exploratory Before-After Study
Pain Management Nursing·2025Open Access
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology·2025· 26 citedOpen Access
Selpercatinib in <i>RET</i> Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
Journal of Clinical Oncology·2025· 13 citedOpen Access
Supplementary Table S2 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2024Open Access
Supplementary Figure S6 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2024Open Access
Supplementary Figure S2 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2024Open Access
Supplementary Figure S1 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2024Open Access
Supplementary Figure S3 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2024Open Access
Supplementary Figure S6 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2024Open Access
Supplementary Figure S3 from Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2024Open Access
page 1 of 24Next →

Frequent Co-authors

Benjamin Besse(11), Alexander Drilon(10), Joachim Diebold(10), Martin Früh(9), Julie Milia(9), Solange Peters(9), Fabrice Barlési(8), Julien Mazières(8), Rolf A. Stahel(8), Vivek Subbiah(7), Sacha I. Rothschild(6), Benjamin Solomon(6), Jürgen Wolf(6), Nir Peled(5), Alessandra Curioni‐Fontecedro(5), Edward Y. Zhu(5), David R. Gandara(5), Miklos Pless(5), Daniel Betticher(5), Thomas Filleron(5)